Effectiveness of Cortiment® in Patients With Ulcerative Colitis

• Status: Completed
• Trial end date: 2018-04-05
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate Cortiment® with regard to its use by clinicians in routine clinical practice and its effectiveness and tolerability in a real-life setting.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ferring Pharmaceuticals
• Treatments: Budesonide

Criteria

Inclusion Criteria:

• Men and women aged ≥ 18 years

• Outpatients

• Patients who have been prescribed Cortiment® for the treatment of mild to moderate active ulcerative colitis within a 5 days' time window prior to being included in the study

• Patients who have received adequate information regarding this non-interventional study and are able to understand and voluntarily sign the Informed Consent

Exclusion Criteria:

• Patients with severe active / fulminant ulcerative colitis

• Patients treated with antibiotics or corticosteroids for the current flare. Use of Antibiotics for other conditions non-related to the gastrointestinal tract, either before enrolment or during the observational period is permitted.

• History of total / sub-total colectomy

• Hypersensitivity to the active substance, lecithin (derived soya oil, peanut oil) or to any of the excipients

• Patients enrolled and involved in an interventional study

• Patients whom investigators consider inappropriate to participate in the study